Results 181 to 190 of about 187,197 (244)

Thermodynamic characterisation of covalent ligand binding

British Journal of Pharmacology, EarlyView.
Background and Purpose Differential scanning fluorimetry (DSF) is a common and straightforward method to evaluate the thermal stability of proteins and has been heavily used for ligand binding characterisation as well as for screening. One class of compounds that is less typically evaluated by DSF are covalent binders.
Rebecca Hertzman, Maayan Lavie, Almog Nadir, Ronen Gabizon, Nir London   +4 more
wiley   +1 more source

RASD2 Drives Renal Clear Cell Carcinoma Progression via RAF1 (Ser338) Phosphorylation

Cancer Science, EarlyView.
RASD2 drives clear cell renal cell carcinoma (ccRCC) progression by physically interacting with RAF1 to induce its Ser338 phosphorylation, which subsequently activates the P38/ERK–MAPK signaling pathway to promote malignant tumor phenotypes and poor prognosis.
Jingxuan Yu, Gang Yu, Yuan Liu, Yu Zhou, Wei Liu, Lin Wang, Lide Liu, Yan Liu, Tiejun Pan, Zhenyu Liu, Lei Gao   +10 more
wiley   +1 more source

A unified mechanism for tubulin cofactors catalyzing α/β-tubulin biogenesis and degradation. [PDF]

Sci Adv
Taheri A, Ashaduzzaman M, Gill V, Eskin JA, Al-Bassam J.   +4 more
europepmc   +1 more source

MiR‐375 in CAFs‐Derived EVs Promotes HCC Progression via Regulating RASA1 and May Potentially Serve as a Biomarker for HCC

Cancer Science, EarlyView.
CAFs could transfer EVs miR‐375 into endothelial cells with a low level of RASA1 and further promote EC angiogenesis. Plasma EVs miR‐375 have the potential values as a novel diagnostic and prognostic biomarker for HCC. ABSTRACT Cancer‐associated fibroblasts (CAFs) in the tumor microenvironment play an important role in cancer initiation and progression
Wei Qin, Li Wang, Beiyuan Hu, Cuicui Xiao, XiaoYing Wu, Huan Tian, Songlin Peng   +6 more
wiley   +1 more source

RASGRP4 is a key factor in the KRAS activation mediated by SOS in tumor Y1 adrenocortical cell lines. [PDF]

Sci Rep
Montoni F, Wailemann RAM, Torres TEP, de Torres KAM, Fonseca CS, da Silva Reis M, Armelin HA.   +6 more
europepmc   +1 more source

Phase II Trial of Nivolumab in Advanced Solid Tumors Based on Genomic Profiling: BELIEVE Trial (NCCH1901) Subcohort

Cancer Science, EarlyView.
Off‐label nivolumab treatment guided by CGP results was evaluated in 56 patients with advanced solid tumors. TMB‐High was the predominant biomarker leading to nivolumab treatment. Nivolumab showed limited clinical benefit in 50 patients with measurable disease, with an ORR of 16.0%, DCR of 40.0%, median PFS of 2.7 months, and median OS of 7.2 months ...
Masashi Kanai, Kuniko Sunami, Tatsunori Shimoi, Satoshi Nishiwaki, Ichiro Kinoshita, Tetsuhiro Yoshinami, Chigusa Morizane, Yusuke Sato, Toshio Kubo, Mamoru Ito, Hiroshi Nishihara, Toru Mukohara, Hidekazu Shirota, Ryo Ko, Taro Shibata, Manabu Muto, Noboru Yamamoto   +16 more
wiley   +1 more source

Riboflavin Biosynthesis: Mapping the Tagged Lines of a Complex Metabolic Design. [PDF]

Biochemistry
Hoffpauir ZA, Lamb AL.
europepmc   +1 more source

Protein Profile of Multiple Myeloma‐Derived Extracellular Vesicles for the Discovery of Novel Myeloma‐Related Biomarkers

Cancer Science, EarlyView.
Comparison of extracellular vesicles with parental cells through proteomic profiling, followed by an integrated bioinformatic pipeline including disease association and transcriptomic analyses, identifies candidate biomarkers for multiple myeloma. Among these, MIF emerges as a clinically relevant marker, supported by validation in patient samples and ...
Natalia Platonova, Gilda Aiello, Domenica Ronchetti, Valentina Citro, Rosanna Asselta, Lavinia Casati, Domenica Giannandrea, Elisa Taiana, Antonino Neri, Gloria Sini, Elisabetta Calzavara, Mauro Turrini, Alfonsina D'Amato, Raffaella Chiaramonte   +13 more
wiley   +1 more source

Extra-large G proteins and their roles in plant development and responses to environmental stresses. [PDF]

Front Plant Sci
Meshram S, Akintayo OF, Bhattacharyya MK.   +2 more
europepmc   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source